Barely Significant
← all excerpts

Eculizumab use in patients with pneumococcal-associated hemolytic uremic syndrome and kidney outcomes.

Pediatr Nephrol · 2023 · PMC10584715 · PMID 37306721

Europe PMCDOI
1
hedged sentence
0.0610
closest p · 1.2× alpha
0.0610
boldest claim

The sentences

did not reach statistical significanceP = 0.061so close (0.05 < p ≤ 0.1)
non-eculizumab group Patients who received eculizumab had a slightly lower C3 complement level and higher maximal LDH measured at the moment of P-HUS diagnosis, but the results did not reach statistical significance (0.45 vs. 0.74 g/l, P = 0.061 for C3 and 112.25 vs. 94.65 μkat/l, P = 0.427), C3 was not obtained on the same day after P-HUS diagnosis (days 0–2) in all cases, and also LDH reached maximum levels on different days.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.